TriangleSAR445877 (NCT07133425)
SAR445877 trial for Non-Small Cell Lung Cancer (NCT07133425). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with locally advanced or metastatic non-small cell lung cancer that progressed after at least six weeks of PD-1/PD-L1 treatment. Other standard-treatment requirements also apply.
The idea: SAR445877 combines PD-1 blockade with an IL-15 signal intended to activate immune cells against cancer. It is infused over one hour every two weeks. Researchers assess safety, tumor control, and biomarkers of response . Repeat tumor biopsies and blood collections are mandatory.
This phase 2 study plans 29 patients. Natalie Vokes leads at MD Anderson in Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.